News | November 12, 2021
Covaxin well tolerated with no safety concerns: Lancet
Covaxin is the only Covid-19 vaccine to have demonstrated efficacy data from phase III clinical trials against the Delta variant at 65.2%
Covaxin is the only Covid-19 vaccine to have demonstrated efficacy data from phase III clinical trials against the Delta variant at 65.2%
Cipla Technologies a subsidiary of Cipla and Pulmatrix had inked a definitive agreement for the co-development and commercialisation of Pulmazole.
Positive results reinforce the improved efficacy seen with Opdivo-based treatments in four Phase 3 clinical trials in earlier-stage cancers, including lung cancer, bladder cancer, esophageal/gastroesophageal junction cancer and melanoma
The new facility will provide an important boost to vaccine capacity in Africa
A Sanofi R&D executive will join the Gyroscope Clinical Advisory Board to advise on matters related to the development of GT005 for geographic atrophy (GA).
Applications remain under review by others including U.S. Food and Drug Administration and the European Medicines Agency
This is the eighth Covid-19 vaccine to receive Emergency Use Listing
It is the first U.S. FDA approved novel topical mechanism for acne in nearly 40 years
The release of this batch will secure the supply for hospitals and cancer centres that are involved in the clinical trials managed by the company
In India, MSD has signed non-exclusive licensing agreements with eight pharma companies.
Subscribe To Our Newsletter & Stay Updated
